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Non-Candida albicans Candida species are increasingly being isolated. These species show differences in
levels of resistance to antimycotic agents and mortality. Therefore, it is important to be able to correctly
identify the causative organism to the species level. Identification of C. dubliniensis in particular remains
problematic due to the high degree of phenotypic similarity between this species and C. albicans. The use of
amplified fragment length polymorphism (AFLP) analysis as an identification method for medically important
Candida species was investigated. Our results show very clear differences among medically important Candida
species. Furthermore, when screening a large collection of clinical isolates previously identified on CHROMagar
as C. albicans, we found a misidentification rate of 6%. AFLP analysis is universally applicable, and the
patterns can easily be stored in a general, accessible database. Therefore, AFLP might prove to be a reliable
method for the identification of medically important Candida species.
In the past decade, the number of life-threatening forms of
candidiasis increased dramatically (1). The attributable mor-
tality of these infections is as high as 38% (34), whereas crude
mortality rates exceed 50% (10, 27, 33). For a long time,
Candida albicans was the main cause of invasive fungal infec-
tions. However, the number of infections by this species is
declining whereas non-albicans Candida species like C. gla-
brata, C. krusei, and C. parapsilosis are increasingly being iso-
lated. At present, non-albicans Candida species account for
approximately 50% of all Candida infections (14).
In cases of candidiasis, it is important to be able to correctly
identify the causative organism to the species level. Different
species show differences in levels of resistance to antimycotic
agents. C. krusei is innately resistant to fluconazole, and C.
glabrata is able to acquire resistance to this drug rapidly. Fur-
thermore, C. glabrata infections have been associated with a
high mortality (11). A particular problem is formed by the
recently recognized species C. dubliniensis. Like C. glabrata,
this species is capable of acquiring stable fluconazole resis-
tance rapidly (22, 23). Identification of C. dubliniensis remains
difficult, due to the high degree of phenotypic similarity be-
tween this species and C. albicans. However, it is known that
genotypically there is more variation between the two species
(30). Therefore, molecular identification methods may be
more reliable than identification methods based on phenotypic
characteristics.
Amplified fragment length polymorphism (AFLP) analysis is
a relatively new technique which has a discriminatory power
that makes it suitable for identification as well as for strain
typing (29, 32). In short, in AFLP analysis genomic DNA is
digested with two restriction enzymes (e.g., EcoRI and MseI)
and double-stranded oligonucleotide adapters are ligated to
the fragments. These adapters serve as targets for the primers
during PCR amplification. To increase the specificity, it is
possible to elongate the primers at their 3 ends with one to
three selective nucleotides. One of the primers is labeled with
a fluorescent dye. The fragments are separated and analyzed
using software packages like BioNumerics (Applied Maths,
Sint-Martens-Latem, Belgium). The advantage of AFLP anal-
ysis is that only a limited amount of DNA is needed since the
fragments are PCR amplified. Furthermore, since stringent
annealing temperatures are used during amplification, the
technique is more reproducible and robust than other methods
such as randomly amplified polymorphic DNA analysis (13,
29). This paper describes the use of AFLP as an identification
method for medically important Candida species, including C.
dubliniensis.
MATERIALS AND METHODS
Yeast strains. The yeast strains and isolates used are listed in Table 1. Ref-
erence strains were obtained from the Centraalbureau voor Schimmelcultures
(CBS), Utrecht, The Netherlands, and the American Type Culture Collection,
Manassas, Va. Clinical isolates were obtained from the European SENTRY
collection (Eijkman-Winkler Center, Utrecht, The Netherlands) (26) and from
the hematology ward of the VU University Medical Center (VUMC), Amster-
dam, The Netherlands. Upon receipt of the SENTRY isolates in the central
laboratory (Eijkman-Winkler Center), CHROMagar (CHROMagar, Paris,
France) was used to distinguish between C. albicans and non-C. albicans species.
Non-C. albicans species were further identified by using the API Candida system
(bioMe´rieux, Marcy-l’Etoile, France). In addition, Vitek YBC cards (bio-
Me´rieux) were used when the results obtained by the API Candida system were
inconclusive or differed from the identification made by the center where the
Candida species was isolated. The isolates from the VUMC were identified using
the germ-tube test. The isolates that were negative in this assay were further
identified by using Vitek YBC (bioMe´rieux).
Extraction of DNA. DNA was extracted from approximately 107 CFU using a
DNeasy tissue kit (Qiagen, West Sussex, England) according to the manufactur-
er’s instructions (protocol for isolation of genomic DNA from yeasts). DNA was
eluted in 100 l of elution buffer (buffer AE of the kit) and stored at 20°C.
AFLP. (i) Restriction and ligation of adapters. The sequences of the adapters
and primers used for AFLP analysis are given in Table 2. DNA was extracted
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TABLE 1. Reference strains and clinical isolates used in this study
Speciesa Strain or isolate(collection) Origin Source
C. albicans CBS 562 Uruguay Skin of man with interdigital mycosis
CBS 1905 Unknown Man
CBS 1912 Norway Sputum of asthma patient
ATCC 90028 Iowa, United States Blood
ATCC 90029 Iowa, United States Blood
04A080 (SENTRY) Paris, France Blood
06A309 (SENTRY) Lille, France Blood
07C069 (SENTRY) Freiburg, Germany Pneumonia
08E058 (SENTRY) Dusseldorf, Germany Wound, skin, or soft tissue
10A173 (SENTRY) Genoa, Italy Blood
10C007 (SENTRY) Genoa, Italy Pneumonia
11A134 (SENTRY) Rome, Italy Blood
11C034 (SENTRY) Rome, Italy Pneumonia
12E033 (SENTRY) Utrecht, The Netherlands Wound, skin, or soft tissue
15A020 (SENTRY) Coimbra, Portugal Blood
15A206 (SENTRY) Coimbra, Portugal Blood
15A561 (SENTRY) Coimbra, Portugal Blood
16A232 (SENTRY) Seville, Spain Blood
16A438 (SENTRY) Seville, Spain Blood
16C088 (SENTRY) Seville, Spain Pneumonia
17A381 (SENTRY) Madrid, Spain Blood
19A164 (SENTRY) Lausanne, Switzerland Blood
19A519 (SENTRY) Lausanne, Switzerland Blood
19A567 (SENTRY) Lausanne, Switzerland Blood
19A568 (SENTRY) Lausanne, Switzerland Blood
23D045 (SENTRY) Ankara, Turkey Urinary tract
TY727 (VUMC) Amsterdam, The Netherlands Oral cavity
TY728 (VUMC) Amsterdam, The Netherlands Oral cavity
TY729 (VUMC) Amsterdam, The Netherlands Oral cavity
TY732 (VUMC) Amsterdam, The Netherlands Feces (human)
C. dubliniensis CBS 7987 Dublin, Ireland Oral cavity of HIV-infected patient
CBS 7988 Melbourne, Australia Oral cavity of HIV-infected patient
CBS 8500 Nijmegen, The Netherlands Blood of 38-year-old woman with chronic
myelogenous leukemia
CBS 8501 Nijmegen, The Netherlands Child with neutropeny induced by chemotherapy
02A038 (SENTRY) Brussels, Belgium Blood
05C118 (SENTRY) Lyon, France Pneumonia
05C121 (SENTRY) Lyon, France Pneumonia
18A221 (SENTRY) Barcelona, Spain Blood
20C149 (SENTRY) London, United Kingdom Pneumonia
23A137 (SENTRY) Ankara, Turkey Blood
C. glabrata CBS 138 Unknown Feces (human)
ATCC 90030 Iowa, United States Blood
TY714 (VUMC) Amsterdam, The Netherlands Oral cavity
TY715 (VUMC) Amsterdam, The Netherlands Feces (human)
TY716 (VUMC) Amsterdam, The Netherlands Oral cavity
TY717 (VUMC) Amsterdam, The Netherlands Oral cavity
TY718 (VUMC) Amsterdam, The Netherlands Oral cavity
TY719 (VUMC) Amsterdam, The Netherlands Oral cavity
TY731 (VUMC) Amsterdam, The Netherlands Oral cavity
C. guilliermondii CBS 566 Unknown Sputum (human)
CBS 2024 Berlin, Germany Ulcer on horse
14A097 (SENTRY) Cracow, Poland Blood
C. krusei CBS 573 Colombo, Sri Lanka Sputum of bronchitic convict
TY722 (VUMC) Amsterdam, The Netherlands Oral cavity
TY723 (VUMC) Amsterdam, The Netherlands Oral cavity
TY726 (VUMC) Amsterdam, The Netherlands Feces (human)
C. lusitaniae CBS 4413 Portugal Cecum of pig
C. parapsilosis CBS 604 Puerto Rico Case of sprue (human)
CBS 2195 Austria Infected nail of 11-year-old boy
Continued on following page
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from approximately 107 CFU of C. albicans as described above. Five microliters
of the DNA samples was added to 5 microliters of restriction-ligation reaction
mixture (1 T4 DNA ligase buffer, 0.05 M NaCl, 0.5 g of bovine serum
albumin, 2 pmol of the EcoRI adapter, 20 pmol of the MseI adapter, 80 U of T4
DNA ligase, 1 U of EcoRI, 1 U of MseI) and incubated overnight at 37°C. All
enzymes were obtained from New England Biolabs (Beverly, Mass.). The mix-
ture was diluted 1:5 with 0.1 TE (5 mM Tris-HCl [pH 7.5], 1 mM EDTA).
(ii) Preselective and selective PCRs. Preselective PCR was performed using
the core sequences, i.e., primers without extensions. The AFLP primers, core
mix, and internal size standard were supplied by Applied Biosystems (Nieu-
werkerk aan den IJssel, The Netherlands). Four microliters of diluted restriction-
ligation product was added to 15 l of AFLP amplification core mix, 0.5 l of the
EcoRI core sequence, and 0.5 l of the MseI core sequence. The mixture was
amplified in a GeneAmp PCR System 9700 machine under the following condi-
tions: 2 min at 72°C, followed by 20 cycles of 20 s at 94°C, 30 s at 56°C, and 2 min
at 72°C. The PCR product was diluted by adding 25 l of sterile double-distilled
water. In a second PCR more-selective primers were used: EcoRI-AC (labeled
with 6-carboxyfluorescein) and MseI-C. The conditions were 2 min at 94°C,
followed by 10 cycles consisting of 20 s at 94°C and 30 s at 66°C (with this
temperature decreasing 1°C with each succeeding cycle), and a final extension of
2 min at 72°C. This sequence was followed by 25 cycles consisting of 20 s at 94°C,
30 s at 56°C, and 2 min at 72°C and a final incubation of 30 min at 60°C.
(iii) Capillary electrophoresis and data analysis. The samples were prepared
for capillary electrophoresis by adding 2 l of the selective PCR product to 24 l
of deionized formamide and 1 l of GeneScan-500 (6-carboxy-X-rhodamine
[ROX] labeled) as an internal size standard. They were run on an ABI 310
genetic analyzer for 30 min each. Data were analyzed with the BioNumerics
software package, version 2.5 (Applied Maths) by using the Pearson correlation
as a similarity coefficient in combination with unweighted pair group method
with arithmatic mean cluster analysis. The statistical reliability of the clusters was
investigated by using the cophenetic values, which calculate the correlation
between the calculated similarities and the dendrogram-derived similarities.
RESULTS AND DISCUSSION
A dendrogram representing all reference strains and clinical
isolates is depicted in Fig. 1. The AFLP patterns of the refer-
ence strains clearly show that each species forms a distinct
cluster. The cophenetic values were 78 for C. albicans, 92 for C.
dubliniensis, 99 for C. glabrata, 84 for C. krusei, 98 for C.
pseudotropicalis, 85 for C. tropicalis, 91 for C. parapsilosis, 98
for C. lusitaniae, and 94 for C. guilliermondii. These results
were highly reproducible.
The C. albicans isolates show two main clusters. One cluster
contains clinical isolates from the VUMC and the SENTRY
collection as well as reference strains from the CBS. The other
cluster contains only isolates from the SENTRY collection.
There is no clear relation between these clusters and the geo-
graphical origins or sources of the isolates. North American C.
albicans isolates show a three-part division by several typing
methods, such as randomly amplified polymorphic DNA anal-
ysis, multilocus enzyme electrophoresis, and Southern blot hy-
bridization with the moderately repetitive C. albicans-specific
Ca3 probe. In South Africa, an additional cluster besides these
three clusters has been found (4, 18, 28). It will be interesting
to investigate whether the two AFLP clusters of C. albicans
correspond with the North American or South African clus-
ters.
The C. dubliniensis isolates also show two clusters whose
isolates have remarkably high similarities (91 and 98%). One
cluster contains all reference strains used and one SENTRY
clinical isolate; the other cluster is composed of SENTRY
isolates only. Using the C. dubliniensis-specific fingerprinting
probe Cd25 on a panel of 98 isolates, Gee et al. also recognized
two different clusters, one of which contained mainly isolates
derived from human immunodeficiency virus (HIV)-infected
individuals, while the other cluster contained mainly isolates
derived from HIV-negative individuals (9). Strains CBS 7987
and CBS 7988, both part of the same AFLP cluster, were
isolated from an HIV-infected individual. However, data on
the HIV status of the patients from which the other isolates
(CBS 8500, CBS 8501, and SENTRY isolates) were obtained
are lacking. Further investigations are necessary to examine
whether the AFLP clusters correspond with the Cd25 clusters.
TABLE 2. Adapter and primer sequences used for AFLP
Adapter or primers Sequencea
Adapters
EcoRI 5-CTCGTAGACTGCGTACC-3
3-CATCTGACGCATGGTTAA-5
MseI 5-GACGATGAGTCCTGAG-3
3-CTACTCAGGACTCAT-5
Primers
EcoRI 5-GACTGCGTACCAATTCAC-3
MseI 5-GATGAGTCCTGAGTAAC-3
a The bold type represents selective nucleotides (added to the core sequence
and used only in the second PCR).
TABLE 1—Continued
Speciesa Strain or isolate(collection) Origin Source
ATCC 90018 Virginia, United States Blood
07A212 (SENTRY) Freiburg, Germany Blood
10A120 (SENTRY) Genoa, Italy Blood
10A311 (SENTRY) Genoa, Italy Blood
14A161 (SENTRY) Cracow, Poland Blood
TY735 (VUMC) Amsterdam, The Netherlands Oral cavity
TY736 (VUMC) Amsterdam, The Netherlands Unknown
C. pseudotropicalis CBS 607 Sri Lanka Bronchitic patient
C. tropicalis CBS 94 Unknown Bronchitic patient
CBS 2310 Unknown Unknown
11D028 (SENTRY) Rome, Italy Urinary tract
TY737 (VUMC) Amsterdam, The Netherlands Oral cavity
TY739 (VUMC) Amsterdam, The Netherlands Oral cavity
a Identification of SENTRY isolates based on AFLP patterns.
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Another noteworthy finding is that all of the AFLP patterns
for the C. glabrata isolates are very similar (90% similarity)
except for that of the CBS reference strain (58% similarity).
This reference strain (CBS 138) was isolated from human feces
and was first described in 1917. The fact that all of the other
isolates studied were clinical isolates which were isolated fairly
recently may account for this difference.
The AFLP patterns of the 18 isolates from the VUMC all
corresponded with the results of the phenotypic identification
(obtained by using the germ-tube test and Vitek YBC cards).
The clinical isolates from the European SENTRY collection
were all originally identified on CHROMagar as being C. al-
bicans. However, based on the AFLP patterns shown in Fig. 1,
some of these strains were presumably misidentified and be-
long to different species. When the total collection of isolates
previously identified as C. albicans (n  213) was screened by
FIG. 1. Dendrogram representing all reference strains and clinical isolates (see also Table 1).
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AFLP analysis, a misidentification rate of 6% was observed. Six
strains are now identified as C. dubliniensis, four are identified
as C. parapsilosis, one is identified as C. tropicalis, and one is
identified as C. guilliermondii (results are partly shown in Fig.
1).
CHROMagar identification of Candida species is based on
differences in colony color. It has been shown that the reliabil-
ity of this method depends on the incubation time and tem-
perature used (2, 24, 35). However, even when optimum con-
ditions are used, the method is not ideal and the differentiation
between C. albicans and C. dubliniensis is especially problem-
atic. Kurzai et al. reported that only 81% of their C. dublini-
ensis isolates showed the dark-green color on CHROMagar,
which is considered indicative of C. dubliniensis (17). Further-
more, 15.9% of their C. albicans isolates also showed a dark-
green coloration instead of the usual lighter green. Tintelnot et
al. (31) reported an even lower number, 57%, of C. dubliniensis
isolates that showed the dark-green coloration on CHROM-
agar, and only 48% of the isolates of Kirkpatrick et al. (15)
showing the dark-green coloration turned out to be C. dublini-
ensis.
Other commercial tests that allow (presumptive) identifica-
tion of C. albicans as well as non-albicans Candida species
usually show high sensitivities and specificities for C. albicans
but are less reliable or need further testing for the identifica-
tion of other, less common species (3, 5, 8, 12). C. dubliniensis-
specific PCR assays as well as generic PCR assays in combina-
tion with species-specific probes have been developed (6, 7, 16,
19, 25). The advantage of AFLP analysis, however, is that this
method is based on the ligation of known sequences (adapters)
to restriction fragments, which function as targets for the PCR
primers. Therefore, the technique is universally applicable. In
the present assay we made use of two subsequent amplifica-
tions, but similar results were obtained when only the second
amplification was used (unpublished observations). The use of
an internal size standard with every sample for normalization
purposes greatly enhances the reproducibility between tests.
Storing all patterns, including those of the reference strains, in
a general, accessible database will provide a screening library
for the identification of Candida species.
Two other universally applicable methods for the identifica-
tion of Candida species have been described: PCR fingerprint-
ing and reference strand-mediated conformational analysis
(20, 21). However, whereas PCR fingerprinting uses mini- and
microsatellite sequences as targets for the primers and refer-
ence strand-mediated conformational analysis is based on 18S
rRNA sequences, AFLP patterns are a representation of the
whole genome. Our results show very clear differences among
medically important Candida species. Therefore, AFLP anal-
ysis might prove to be a reliable method for the identification
of medically important Candida species, including C. dublini-
ensis.
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